Find a Trial

Trial Results


17 protocol(s) meet the specified criteria
14-13546OPEN TO ACCRUAL
Pathogen Identification in Pediatric Hematopoietic Stem Cell Transplant Patients with Suspected Lower Respiratory Tract Infection
20170543OPEN TO ACCRUAL
A Phase 1, First-in-Human, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 510 in Subjects With Advanced Solid Tumors With a Specific KRAS Mutation.
A081105OPEN TO ACCRUAL
RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY OF ERLOTINIB OR PLACEBO IN PATIENTS WITH COMPLETELY RESECTED EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTANT NON-SMALL CELL LUNG CANCER (NSCLC)
A151216OPEN TO ACCRUAL
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
BBI608-201OPEN TO ACCRUAL
A Phase Ib/II Clinical Study of BBI608 Administered with Paclitaxel in Adult Patients with Advanced Malignancies
BTCRC-LUN16-081OPEN TO ACCRUAL
Phase II Study of Consolidation Immunotherapy with Nivolumab and Ipilimumab or Nivolumab alone following Concurrent Chemoradiotherapy for Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC)
BTCRC-LUN17-139OPEN TO ACCRUAL
A randomized phase II study of Carboplatin plus Pemetrexed plus Atezolizumab plus Bevacizumab in chemotherapy and immunotherapy-naive patients with stage IV non-squamous non-small cell lung cancer: Big Ten Cancer Research Consortium BTCRC-LUN17-139
BTCRCLUN15-029OPEN TO ACCRUAL
A Phase II Trial of Chemotherapy plus Pembrolizumab in patients with advanced NSCLC previously treated with PD-1 or PD-L1 Inhibitor
E4512OPEN TO ACCRUAL
A Phase III Double Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
EA5142OPEN TO ACCRUAL
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) ? A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
IUSCC-0580OPEN TO ACCRUAL
Blood Based Recurrence Detection for Patients with Lung Cancer Receiving Radiation Therapy
IUSCC-0624OPEN TO ACCRUAL
Phase I/II trial evaluating five fraction SABR dose escalation for early stage Squamous Cell Carcinoma of the Lung
IUSCC-0626OPEN TO ACCRUAL
Phase II Evaluation with Safety Run-in of Stereotactic Ablative Body Radiation for T1-2a N1 Lung Cancer
IUSCC-0662OPEN TO ACCRUAL
Randomized controlled pilot study to evaluate fasting-mimicking diet in patients receiving chemo-immunotherapy for treatment of metastatic non-small cell lung cancer
IUSCC-0695OPEN TO ACCRUAL
Survey of Health and Well-Being in Advanced Lung Cancer Patients
NKTR16-214-02OPEN TO ACCRUAL
A PHASE 1/2, OPEN-LABEL, MULTICENTER STUDY OF THE COMBINATION OF NKTR 214 AND NIVOLUMAB OR THE COMBINATION OF NKTR 214, NIVOLUMAB, AND IPILIMUMAB IN PATIENTS WITH SELECT LOCALLY ADVANCED OR METASTATIC SOLID TUMOR MALIGNANCIES
NURS-IIR-CHARRIS-LCSOPEN TO ACCRUAL
Lung Cancer Screening: Identifying Factors Associated with Participantion